Assembly Biosciences (NASDAQ:ASMB) Upgraded at Wall Street Zen

Assembly Biosciences (NASDAQ:ASMB) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

A number of other analysts also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, December 22nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $41.75.

Assembly Biosciences Price Performance

Shares of NASDAQ:ASMB opened at $28.46 on Friday. Assembly Biosciences has a 1 year low of $7.75 and a 1 year high of $39.71. The company has a market capitalization of $450.24 million, a PE ratio of -38.46 and a beta of 1.11. The business has a fifty day moving average price of $28.16 and a two-hundred day moving average price of $29.58.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $2.99. The company had revenue of $42.47 million for the quarter, compared to analysts’ expectations of $7.42 million. Assembly Biosciences had a negative return on equity of 8.06% and a negative net margin of 8.47%. Sell-side analysts anticipate that Assembly Biosciences will post -6.87 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ellsworth Advisors LLC purchased a new stake in Assembly Biosciences in the 3rd quarter worth about $852,000. Commodore Capital LP bought a new position in Assembly Biosciences during the third quarter worth about $25,600,000. Farallon Capital Management LLC bought a new position in Assembly Biosciences during the third quarter worth about $31,426,000. Patient Square Capital LP purchased a new position in shares of Assembly Biosciences in the third quarter worth about $3,461,000. Finally, Palumbo Wealth Management LLC increased its stake in shares of Assembly Biosciences by 86.4% in the third quarter. Palumbo Wealth Management LLC now owns 34,798 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 16,131 shares in the last quarter. Institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.